Vitamin B6, Vitamin B9 and Vitamin B12: study protocols
10 study groups took Vitamin B6 together with Vitamin B9 and Vitamin B12. These are the doses the studies gave. They are not a recommendation.
Dose per serving from research: Vitamin B6
10 study groups in 8 studies say how much Vitamin B6 participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 25 mg to 50 mg, 60% of 10 study groups.
| Daily dose | Study groups |
|---|---|
| 1 mg or less | 1 |
| 1 mg to 2.5 mg | 0 |
| 2.5 mg to 5 mg | 2 |
| 5 mg to 10 mg | 0 |
| 10 mg to 25 mg | 0 |
| 25 mg to 50 mg | 6 |
| 50 mg to 100 mg | 1 |
Dose per serving from research: Vitamin B9
10 study groups in 8 studies say how much Vitamin B9 participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 10 mg to 25 mg, 50% of 10 study groups.
| Daily dose | Study groups |
|---|---|
| 250 mcg or less | 1 |
| 250 mcg to 500 mcg | 1 |
| 500 mcg to 1 mg | 2 |
| 1 mg to 2.5 mg | 1 |
| 2.5 mg to 5 mg | 0 |
| 5 mg to 10 mg | 0 |
| 10 mg to 25 mg | 5 |
Dose per serving from research: Vitamin B12
10 study groups in 8 studies say how much Vitamin B12 participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 500 mcg to 1 mg, 60% of 10 study groups.
| Daily dose | Study groups |
|---|---|
| 5 mcg or less | 1 |
| 5 mcg to 10 mcg | 0 |
| 10 mcg to 25 mcg | 2 |
| 25 mcg to 50 mcg | 0 |
| 50 mcg to 100 mcg | 0 |
| 100 mcg to 250 mcg | 0 |
| 250 mcg to 500 mcg | 1 |
| 500 mcg to 1 mg | 6 |
Commonly used together
3 of 10 study groups took Vitamin B6, Vitamin B9 and Vitamin B12 with something else, but nothing that 3 or more different studies gave.
10 study groups
| Study | |||||
|---|---|---|---|---|---|
| B vitamin and/or n-3 fatty acid supplementation and health-related quality of life: ancillary findings from the SU.FOL.OM3 randomized trial 2014 · B vitamins only · Adults aged 45–80 with a recent history of myocardial infarction, unstable angina, or ischemic stroke | 3 mg | 560 mcg | 20 mcg | 1716 days | — |
| Effect of a Combination of Magnesium, B Vitamins, Rhodiola, and Green Tea (L-Theanine) on Chronically Stressed Healthy Individuals-A Randomized, Placebo-Controlled Study 2022 · Mg-Teadiola · Adults aged 18–65, either sex, otherwise healthy and chronically stressed (DASS-42 stress score ≥14) | 700 mcg | 100 mcg | 1.25 mcg | 4 weeks | 51 |
| B vitamin and/or n-3 fatty acid supplementation and health-related quality of life: ancillary findings from the SU.FOL.OM3 randomized trial 2014 · B vitamins plus n-3 fatty acids · Adults aged 45–80 with a recent history of myocardial infarction, unstable angina, or ischemic stroke | 3 mg | 560 mcg | 20 mcg | 1716 days | — |
| Distribution of plasma folate forms in hemodialysis patients receiving high daily doses of L-folinic or folic acid 2002 · Folinic acid group · Adults with chronic stable hemodialysis and hyperhomocysteinemia | 50 mg | 20 mg | 1 mg | 12 weeks | 22 |
| Effect of Methylfolate, Pyridoxal-5'-Phosphate, and Methylcobalamin (Soloways(TM)) Supplementation on Homocysteine and Low-Density Lipoprotein Cholesterol Levels in Patients with Methylenetetrahydrofolate Reductase, Methionine Synthase, and Methionine Synthase Reductase Polymorphisms: A Randomized Controlled Trial 2024 · methylfolate, P5P, and methylcobalamin · Adults aged 40–75 with elevated homocysteine, LDL-C of 70–190 mg/dL, and at least one minor allele in a specified MTHFR, MTR, or MTRR polymorphism | 100 mg | 2 mg | 1 mg | 180 days | 27 |
| Controlled comparison of L-5-methyltetrahydrofolate versus folic acid for the treatment of hyperhomocysteinemia in hemodialysis patients 2000 · MTHF group · Adults with chronic, stable hyperhomocysteinemia receiving hemodialysis | 50 mg | 17 mg | 1 mg | 12 weeks | 25 |
| Treatment of hyperhomocysteinemia in hemodialysis patients and renal transplant recipients 2001 · MTHF group · Adults with chronic, stable hyperhomocysteinemia receiving maintenance hemodialysis | 50 mg | 17 mg | 1 mg | 12 weeks | 25 |
| Rapid communication: L-folinic acid versus folic acid for the treatment of hyperhomocysteinemia in hemodialysis patients 2001 · L-folinic acid group · Adults with chronic, stable hyperhomocysteinemia receiving hemodialysis | 50 mg | 20 mg | 1 mg | 12 weeks | 24 |
| Treatment of hyperhomocysteinemia in hemodialysis patients and renal transplant recipients 2001 · Hemodialysis patients receiving MTHF · Hemodialysis patients with hyperhomocysteinemia and baseline total homocysteine comparable to the renal transplant recipients | 50 mg | 17 mg | 1 mg | 12 weeks | — |
| Effect of adding B-vitamins to vitamin D and calcium supplementation on CpG methylation of epigenetic aging markers 2018 · D + Ca + B · Adults, mean age 68.4 years; no specific condition stated | 50 mg | 500 mcg | 500 mcg | 1 year | 32 |